Form 8-K - Current report:
SEC Accession No. 0001437749-25-003319
Filing Date
2025-02-10
Accepted
2025-02-10 16:55:11
Documents
15
Period of Report
2025-02-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K vxrt20250210_8k.htm   iXBRL 8-K 31516
2 EXHIBIT 10.1 ex_776577.htm EX-10.1 475117
  Complete submission text file 0001437749-25-003319.txt   679237

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vxrt-20250207.xsd EX-101.SCH 3409
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vxrt-20250207_def.xml EX-101.DEF 11424
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE vxrt-20250207_lab.xml EX-101.LAB 15310
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vxrt-20250207_pre.xml EX-101.PRE 11584
17 EXTRACTED XBRL INSTANCE DOCUMENT vxrt20250210_8k_htm.xml XML 2830
Mailing Address 170 HARBOR WAY, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 170 HARBOR WAY, SUITE 300 SOUTH SAN FRANCISCO CA 94080 (650) 550-3500
Vaxart, Inc. (Filer) CIK: 0000072444 (see all company filings)

EIN.: 591212264 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35285 | Film No.: 25606426
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)